Back to User profile » Mr Robert P Wood
Papers published by Mr Robert P Wood:
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study
Czira A, Akiyama S, Ishii T, Wood RP, Camidge LJ, Wallis H, Jennison T, Wild RAC, Yarita M, Hashimoto K, Rothnie KJ, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2933-2953
Published Date: 8 December 2023
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJ, Quint JK, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2039-2054
Published Date: 15 September 2023
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1431-1444
Published Date: 13 July 2023
Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:643-659
Published Date: 19 April 2023
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:231-245
Published Date: 5 March 2023
Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
Halpin DM, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, Tritton T, Massey O, Wild R, Snowise N, Nikitin K, Sharma R, Ismaila AS, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2417-2429
Published Date: 24 September 2022
Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1781-1795
Published Date: 10 August 2022
Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
Sansbury LB, Wood RP, Anley GA, Nam Y, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2795-2808
Published Date: 8 October 2021
COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners
Meeraus W, Wood R, Jakubanis R, Holbrook T, Bizouard G, Despres J, Correia Da Silva C, Nachbaur G, Landis SH, Punekar Y, Aguilaniu B, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:51-63
Published Date: 18 December 2018
Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
Taylor PC, Alten R, Gomez Reino JJ, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M
Patient Preference and Adherence 2018, 12:2007-2014
Published Date: 4 October 2018
The impacts of morning, daytime, and nighttime symptoms on disease burden in real-world patients with COPD
Muñoz A, Small M, Wood R, Ribera A, Nuevo J
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1557-1568
Published Date: 15 May 2018
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V
Diabetes, Metabolic Syndrome and Obesity 2017, 10:403-412
Published Date: 29 September 2017